Study to Evaluate the Respiratory Safety of Lemborexant in Adult and Elderly Healthy Subjects and Adult and Elderly Subjects With Mild Obstructive Sleep Apnea
Study Details
Study Description
Brief Summary
This study will be conducted to determine whether lemborexant as compared to placebo decreases the peripheral oxygen saturation during total sleep time in healthy adult and elderly participants after a single dose of treatment and to determine whether it increases the apnea-hypopnea index after single and multiple doses of treatment in adult and elderly participants with mild obstructive sleep apnea (OSA).
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Healthy Volunteer (HV) Cohort:
The HV Cohort comprises a randomized, double-blind, placebo-controlled, 3-period crossover study. Eligible healthy adult and elderly participants will be randomized to treatment sequence A, B, or C, each consisting of 3 Treatment Periods, each of one night's duration, in which participants will receive a single dose of lemborexant 10 milligrams (mg), or lemborexant 25 mg, or placebo. Treatment Periods will be separated by a washout interval of at least 14 days. A sufficient number of participants will be randomized to ensure that 8 evaluable adult participants (<65 years) and 4 evaluable elderly participants (≥65 years) complete the study.
OSA Cohort:
The OSA Cohort comprises a multiple-dose, randomized, double-blind, placebo-controlled, 2-period crossover study. Adult and elderly participants with mild OSA will be randomized to treatment sequence D or E, each consisting of 2 Treatment Periods, each of 8 nights' duration, in which participants will receive lemborexant 10 mg or placebo. The Treatment Periods will be separated by a washout interval of at least 14 days. A sufficient number of participants will be randomized to ensure that 20 evaluable adult participants (<65 years) and 10 evaluable elderly participants (≥65 years) complete the study.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: HV Cohort,Sequence A:Placebo,Lemborexant 10mg,Lemborexant 25mg Eligible healthy adult and elderly participants will receive lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period. |
Drug: Placebo
HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).
Drug: Lemborexant 10 mg
HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
Drug: Lemborexant 25 mg
HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
|
| Experimental: HV Cohort,Sequence B:Lemborexant 10mg,Lemborexant 25mg,Placebo Eligible healthy adult and elderly participants will receive lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 1, followed by lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 2, and then lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period. |
Drug: Placebo
HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).
Drug: Lemborexant 10 mg
HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
Drug: Lemborexant 25 mg
HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
|
| Experimental: HV Cohort,Sequence C:Lemborexant 25mg,Placebo,Lemborexant 10mg Eligible healthy adult and elderly participants will receive lemborexant 25 mg (2 lemborexant 10 mg tablet and 1 lemborexant 5 mg tablet) on the night of Day 1 of Treatment Period 1, followed by lemborexant-matched placebo (3 matched tablets) on the night of Day 1 of Treatment Period 2, and then lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets) on the night of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each Treatment Period. |
Drug: Placebo
HV: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off).
Drug: Lemborexant 10 mg
HV: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
Drug: Lemborexant 25 mg
HV: 25 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off).
|
| Experimental: OSA Cohort, Sequence D: Placebo, Lemborexant 10mg Eligible adult and elderly participants with mild OSA will receive one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period. |
Drug: Placebo
OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
Drug: Lemborexant 10 mg
OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
|
| Experimental: OSA Cohort, Sequence E: Lemborexant 10mg, Placebo Eligible adult and elderly participants with mild OSA will receive one lemborexant 10 mg tablet on the night of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo tablet on the night of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each Treatment Period. |
Drug: Placebo
OSA: Lemborexant-matched oral placebo will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
Drug: Lemborexant 10 mg
OSA: 10 mg oral lemborexant will be administered at bedtime in the clinic (within 5 minutes of lights off) in the evening of Days 1 and 8. On Days 2 to 7, participants will take study drug at home, immediately (within 5 minutes) of the time they intend to try to sleep.
|
Outcome Measures
Primary Outcome Measures
- HV Cohort: Peripheral Oxygen Saturation (SpO2) During Total Sleep Time (TST) on Day 1 of Treatment [Day 1]
SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 was monitored by noninvasive method known as transmissive pulse oximetry. TST was defined as the total time asleep in minutes using polysomnography (PSG).
- OSA Cohort: Apnea-Hypopnea Index (AHI) on Day 8 of Treatment [Day 8]
The AHI is the number of apneas and hypopneas per hour of sleep. AHI less than 5 is considered normal. An AHI from 5 to 14 denotes mild sleep apnea, 15 to 30 is moderate, while a greater than 30 AHI is considered severe.
Secondary Outcome Measures
- HV Cohort: AHI on Day 1 of Treatment [Day 1]
The AHI is the number of apneas and hypopneas per hour of sleep. AHI less than 5 is considered normal. An AHI from 5 to 14 denotes mild sleep apnea, 15 to 30 is moderate, while a greater than 30 AHI is considered severe.
- OSA Cohort: AHI on Day 1 of Treatment [Day 1]
The AHI is the number of apneas and hypopneas per hour of sleep. AHI less than 5 is considered normal. An AHI from 5 to 14 denotes mild sleep apnea, 15 to 30 is moderate, while a greater than 30 AHI is considered severe.
- HV Cohort: Percentage of TST During Which SpO2 Was Less Than (<) 90 Percent (%), 85 % and 80 % on Day 1 of Treatment [Day 1]
TST was defined as the total time asleep in minutes using PSG. SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 was monitored by noninvasive method known as transmissive pulse oximetry.
- HV Cohort: Percentage of Participants With at Least One Incident of SpO2 <90% for at Least 30 Seconds During TST on Day 1 of Treatment [Day 1]
SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 was monitored by noninvasive method known as transmissive pulse oximetry. TST was defined as the total time asleep in minutes using PSG.
- OSA Cohort: SpO2 During TST on Day 1 and Day 8 of Treatment [Day 1 and Day 8]
SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 was monitored by noninvasive method known as transmissive pulse oximetry. TST was defined as the total time asleep in minutes using PSG.
- OSA Cohort: Percentage of TST During Which the SpO2 is <90%, 85% and 80 % on Day 1 and Day 8 of Treatment [Day 1 and Day 8]
TST was defined as the total time asleep in minutes using PSG. SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 was monitored by noninvasive method known as transmissive pulse oximetry.
- OSA Cohort: Percentage of Participants With at Least One Incident of SpO2 <90% for at Least 30 Seconds During TST on Day 1 and Day 8 of Treatment [Day 1 and Day 8]
SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 was monitored by noninvasive method known as transmissive pulse oximetry. TST was defined as the total time asleep in minutes using PSG.
Eligibility Criteria
Criteria
Inclusion Criteria:
Participants must meet all of the following criteria to be included in this study:
-
Male or female, age ≥18 years and ≤90 years at the time of informed consent
-
Voluntary agreement and ability to provide written informed consent
-
Reports habitually sleeping for at least 5.5 hours per night
-
Agrees to stay in bed for 7 hours per night for the duration of treatment
-
Reports habitual bedtime between 21:00 and 01:00
-
Peripheral capillary oxygen saturation (SpO2) ≥94% assessed as part of vital signs at Screening Visit 1
Additional Inclusion Criteria (Healthy Volunteer [HV] Cohort):
-
Body mass index (BMI) less than or equal to 32 kilograms per meters squared (kg/m^2)
-
On screening polysomnography (PSG) (Screening Visit 2): apnea-hypopnea index (AHI) <5
Additional Inclusion Criteria (Obstructive Sleep Apnea [OSA] Cohort):
-
BMI ≤40 kg/m^2
-
OSA, diagnosed according to the criteria of the International Classification of Sleep Disorders, version 3
-
On Screening PSG: AHI ≥5 to <15 (mild severity)
Exclusion Criteria:
-
A current diagnosis of restless legs syndrome, periodic limb movement disorder, circadian rhythm sleep disorder, or narcolepsy
-
Reports symptoms potentially related to narcolepsy, that in the clinical opinion of the investigator indicate the need for referral for a diagnostic evaluation for the presence of narcolepsy
-
A history of a parasomnia or parasomnia observed on the Screening PSG that in the investigator's opinion makes the participant unsuitable for the study
-
Periodic Limb Movement with Arousal Index (PLMAI) as measured on the Screening PSG:
-
Age 18 to <65 years: PLMAI ≥10
-
Age ≥65 years: PLMAI >15
-
History of or suspected drug or alcohol use disorder within approximately 2 previous years
-
A positive urine drug test or breath alcohol test at Screening or Baseline, or unwilling to refrain from use of recreational drugs during the study
-
Known to be human immunodeficiency virus positive
-
Active viral hepatitis (B or C) as demonstrated by positive viral serology at Screening
-
A prolonged QT/corrected QT (QTc) interval (QT interval corrected for heart rate using Fridericia's formula [QTcF] >450 milliseconds [ms]) as demonstrated by a repeated electrocardiogram (ECG) at Screening (repeated if initial ECG indicates a QTcF interval >450 ms)
-
Comorbid nocturia resulting in the need to get out of bed to use the bathroom more than 3 times during the night
-
Any history of medical or psychiatric condition that in the opinion of the investigator could affect the participant's safety or interfere with the study assessments
-
Any suicidal ideation with intent to act with or without a plan, current or within 6 months before the Columbia - Suicide Severity Rating Scale (C-SSRS) administration during the Screening (e.g., answering "Yes" to questions 4 or 5 on the Suicidal Ideation section of the C-SSRS
-
Any suicidal behavior (per the Suicidal Behavior section of the C-SSRS) within 10 years of Screening
-
Scheduled for surgery during the study that requires general anesthesia or administration of prohibited medications
-
Used any prohibited prescription or over-the-counter medications within 1 week or 5 half-lives, whichever is longer, before the Screening PSG
-
Hypersensitivity to lemborexant or excipients
-
Currently enrolled in another interventional clinical trial or used any investigational drug or device within 30 days or 5 times the half-life, whichever is longer preceding informed consent
-
Previously participated in other clinical trial of lemborexant
-
Is unable to avoid working a night shift within 2 weeks before the Screening PSG, or between the Screening PSG and End-of-Study
-
Has travelled across 3 or more time zones in the week prior to Screening, or plans to travel across more than 3 time zones during the study
-
Clinically significant findings based on vital signs, physical examination, ECG, or clinical laboratory tests
Additional Exclusion Criteria (HV Cohort):
-
Any valid event of SpO2 <90% during the Screening PSG
-
Current evidence of a clinically significant, active respiratory disorder. This includes bronchiectasis, emphysema, asthma, chronic obstructive pulmonary disease, or any other pulmonary disorder identified by review of medical history, physical examination, and which in the opinion of the investigator, could compromise the participant's safety or interfere with study assessments
-
Presence of significant illness (including insomnia) that requires treatment or may influence the study assessments (e.g., psychiatric disorders, disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, cardiovascular system, or a congenital abnormality), malignancy within the past 5 years (other than adequately treated basal cell carcinoma or in situ carcinoma of the cervix), or chronic pain that in the opinion of the investigator could interfere with the study assessments. Participants for whom a sedating drug would be contraindicated for safety reasons because of the participant's occupation or activities are also excluded
Additional Exclusion Criteria (OSA Cohort):
-
SpO2 less than 80% for ≥ 5% of total sleep time during the Screening PSG
-
Uses or plans to use of continuous positive airway pressure device or dental appliance within 2 weeks of the Screening PSG (Screening Visit 2) or during the study
-
Current evidence of a clinically significant, active respiratory disorder other than OSA. This includes bronchiectasis, emphysema, asthma, chronic obstructive pulmonary disease or any other pulmonary disorder identified by review of medical history, physical examination, and which in the opinion of the investigator, could compromise the participant's safety or interfere with study assessments
-
Current evidence of other clinically significant disease (e.g., psychiatric disorders, disorders of the gastrointestinal tract, liver, kidney, respiratory system, endocrine system, hematological system, neurological system, cardiovascular system, or a congenital abnormality), malignancy within the past 5 years (other than adequately treated basal cell carcinoma or in situ carcinoma of the cervix), or chronic pain that in the opinion of the investigator could affect the participant's safety or interfere with the study assessments. Participants for whom a sedating drug would be contraindicated for safety reasons because of the participant's occupation or activities are also excluded. Participants with insomnia disorder, who complain of difficulties with sleep onset and/or sleep maintenance, are eligible provided that they meet this criterion. Note that medications to treat insomnia are prohibited.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | PACT | Glendale | Arizona | United States | 85306 |
| 2 | Pulmonary Associates, PA | Phoenix | Arizona | United States | 85006 |
| 3 | Pacific Research Network. LLC | San Diego | California | United States | 92103 |
| 4 | PAB Clinical Research | Brandon | Florida | United States | 33511 |
| 5 | Research Centers of America | Hollywood | Florida | United States | 33024 |
| 6 | Neurotrials Research, Inc | Atlanta | Georgia | United States | 30342 |
| 7 | The Center for Sleep & Wake Disorders | Chevy Chase | Maryland | United States | 20815 |
| 8 | Advarra | Columbia | Maryland | United States | 21046 |
| 9 | Clinilabs Drug Development | New York | New York | United States | 10019 |
| 10 | CTI Clinical Research Center | Cincinnati | Ohio | United States | 45212 |
| 11 | Community Research | Cincinnati | Ohio | United States | 45227 |
Sponsors and Collaborators
- Eisai Inc.
- Purdue Pharma LP
Investigators
None specified.Study Documents (Full-Text)
More Information
Publications
None provided.- E2006-A001-102
Study Results
Participant Flow
| Recruitment Details | Participants took part in the study at 8 investigative sites in the United States from February 21, 2018 to August 3, 2018. |
|---|---|
| Pre-assignment Detail | In healthy volunteer (HV) cohort, 39 participants were screened and enrolled, of which 22 were screen failures, 17 were randomized to receive treatment. In obstructive sleep apnea (OSA) cohort, 107 participants were screened and enrolled, of which 68 were screen failures, 39 were randomized to receive treatment. Total participants enrolled=146 |
| Arm/Group Title | HV Cohort,Sequence A:Placebo,Lemborexant 10mg,Lemborexant 25mg | HV Cohort,Sequence B:Lemborexant 10mg,Lemborexant 25mg,Placebo | HV Cohort,Sequence C:Lemborexant 25mg,Placebo,Lemborexant 10mg | OSA Cohort, Sequence D: Placebo, Lemborexant 10mg | OSA Cohort, Sequence E: Lemborexant 10mg, Placebo |
|---|---|---|---|---|---|
| Arm/Group Description | Eligible healthy adult and elderly participants received lemborexant-matched placebo (3 placebo tablets), orally, once, in the evening (within 5 minutes of lights off) of Day 1 of Treatment Period 1, followed by lemborexant 10 mg (milligram) (1 lemborexant 10 mg tablet and 2 matching placebo tablets [to maintain blind]), orally, once, in the evening (within 5 minutes of lights off) of Day 1 of Treatment Period 2, and then lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet), orally, once, in the evening (within 5 minutes of lights off) of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each treatment period. | Eligible healthy adult and elderly participants received lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets [to maintain blind]), orally, once, in the evening (within 5 minutes of lights off) of Day 1 of Treatment Period 1, followed by lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet), orally, once, in the evening (within 5 minutes of lights off) of Day 1 of Treatment Period 2, and then lemborexant-matched placebo (3 placebo tablets), orally, once, in the evening (within 5 minutes of lights off) of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each treatment period. | Eligible healthy adult and elderly participants received lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet), orally, once, in the evening (within 5 minutes of lights off) of Day 1 of Treatment Period 1, followed by lemborexant-matched placebo (3 placebo tablets), orally, once, in the evening (within 5 minutes of lights off) of Day 1 of Treatment Period 2, and then lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets [to maintain blind]), orally, once, in the evening (within 5 minutes of lights off) of Day 1 of Treatment Period 3. A washout period of 14 days was maintained between each treatment period. | Eligible adult and elderly participants with mild OSA received one lemborexant-matched placebo, tablet, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant 10 mg, tablet, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each treatment period. | Eligible adult and elderly participants with mild OSA received one lemborexant 10 mg, tablet, orally, once in the evening of Day 1 through Day 8 of Treatment Period 1, followed by one lemborexant-matched placebo, tablet, orally, once, in the evening of Day 1 through Day 8 of Treatment Period 2. A washout period of 14 days was maintained between each treatment period. |
| Period Title: Treatment Period 1(HV:1 Day, OSA:8 Days) | |||||
| STARTED | 6 | 5 | 6 | 19 | 20 |
| Treated | 6 | 5 | 6 | 18 | 20 |
| COMPLETED | 6 | 5 | 5 | 18 | 19 |
| NOT COMPLETED | 0 | 0 | 1 | 1 | 1 |
| Period Title: Treatment Period 1(HV:1 Day, OSA:8 Days) | |||||
| STARTED | 6 | 5 | 5 | 18 | 19 |
| COMPLETED | 6 | 5 | 5 | 18 | 19 |
| NOT COMPLETED | 0 | 0 | 0 | 0 | 0 |
| Period Title: Treatment Period 1(HV:1 Day, OSA:8 Days) | |||||
| STARTED | 6 | 5 | 5 | 18 | 19 |
| COMPLETED | 6 | 5 | 5 | 18 | 18 |
| NOT COMPLETED | 0 | 0 | 0 | 0 | 1 |
| Period Title: Treatment Period 1(HV:1 Day, OSA:8 Days) | |||||
| STARTED | 6 | 5 | 5 | 0 | 0 |
| COMPLETED | 6 | 5 | 5 | 0 | 0 |
| NOT COMPLETED | 0 | 0 | 0 | 0 | 0 |
| Period Title: Treatment Period 1(HV:1 Day, OSA:8 Days) | |||||
| STARTED | 6 | 5 | 5 | 0 | 0 |
| COMPLETED | 6 | 5 | 5 | 0 | 0 |
| NOT COMPLETED | 0 | 0 | 0 | 0 | 0 |
| Period Title: Treatment Period 1(HV:1 Day, OSA:8 Days) | |||||
| STARTED | 6 | 5 | 5 | 18 | 18 |
| COMPLETED | 6 | 5 | 5 | 17 | 17 |
| NOT COMPLETED | 0 | 0 | 0 | 1 | 1 |
Baseline Characteristics
| Arm/Group Title | HV Cohort | OSA Cohort | Total |
|---|---|---|---|
| Arm/Group Description | Eligible healthy adult and elderly participants received lemborexant-matched placebo (3 placebo tablets), lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets [to maintain blind]) or lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. A washout period of 14 days was maintained between each treatment period. | Eligible adult and elderly participants with mild OSA received one lemborexant-matched placebo or one lemborexant 10 mg, tablets, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 in the respective Treatment Period 1 or 2. A washout period of 14 days was maintained between each treatment period. | Total of all reporting groups |
| Overall Participants | 17 | 39 | 56 |
| Age (Count of Participants) | |||
| <=18 years |
0
0%
|
0
0%
|
0
0%
|
| Between 18 and 65 years |
10
58.8%
|
26
66.7%
|
36
64.3%
|
| >=65 years |
7
41.2%
|
13
33.3%
|
20
35.7%
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
12
70.6%
|
24
61.5%
|
36
64.3%
|
| Male |
5
29.4%
|
15
38.5%
|
20
35.7%
|
| Ethnicity (NIH/OMB) (Count of Participants) | |||
| Hispanic or Latino |
1
5.9%
|
16
41%
|
17
30.4%
|
| Not Hispanic or Latino |
16
94.1%
|
23
59%
|
39
69.6%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
| Race (NIH/OMB) (Count of Participants) | |||
| American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
| Asian |
0
0%
|
0
0%
|
0
0%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
1
2.6%
|
1
1.8%
|
| Black or African American |
8
47.1%
|
3
7.7%
|
11
19.6%
|
| White |
9
52.9%
|
35
89.7%
|
44
78.6%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
0
0%
|
0
0%
|
0
0%
|
Outcome Measures
| Title | HV Cohort: Peripheral Oxygen Saturation (SpO2) During Total Sleep Time (TST) on Day 1 of Treatment |
|---|---|
| Description | SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 was monitored by noninvasive method known as transmissive pulse oximetry. TST was defined as the total time asleep in minutes using polysomnography (PSG). |
| Time Frame | Day 1 |
Outcome Measure Data
| Analysis Population Description |
|---|
| Pharmacodynamic (PD) analysis set included group of participants who received at least 1 dose of study drug in each treatment periods and who had sufficient PD data to derive at least 1 primary PD parameter. |
| Arm/Group Title | HV Cohort: Placebo | HV Cohort: Lemborexant 10 mg | HV Cohort: Lemborexant 25 mg |
|---|---|---|---|
| Arm/Group Description | Eligible healthy adult and elderly participants received lemborexant-matched placebo (3 placebo tablets), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. | Eligible healthy adult and elderly participants received lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets [to maintain blind]), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. | Eligible healthy adult and elderly participants received lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. |
| Measure Participants | 16 | 16 | 16 |
| Mean (Standard Deviation) [percentage of oxygen saturation] |
95.34
(0.900)
|
95.00
(1.283)
|
95.07
(1.311)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.099 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | Mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | Least squares (LS) mean difference |
| Estimated Value | -0.36 | |
| Confidence Interval |
(2-Sided) 95% -0.78 to 0.07 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 25 mg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.176 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | Mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | -0.29 | |
| Confidence Interval |
(2-Sided) 95% -0.72 to 0.14 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | OSA Cohort: Apnea-Hypopnea Index (AHI) on Day 8 of Treatment |
|---|---|
| Description | The AHI is the number of apneas and hypopneas per hour of sleep. AHI less than 5 is considered normal. An AHI from 5 to 14 denotes mild sleep apnea, 15 to 30 is moderate, while a greater than 30 AHI is considered severe. |
| Time Frame | Day 8 |
Outcome Measure Data
| Analysis Population Description |
|---|
| PD analysis set included group of participants who received at least 1 dose of study drug in each treatment periods and who had sufficient PD data to derive at least 1 primary PD parameter. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure. |
| Arm/Group Title | OSA Cohort: Placebo | OSA Cohort: Lemborexant 10 mg |
|---|---|---|
| Arm/Group Description | Eligible adult and elderly participants with mild OSA received one lemborexant-matched placebo, tablet, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 in the respective Treatment Period 1 or 2. | Eligible adult and elderly participants with mild OSA received one lemborexant 10 mg, tablet, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 in the respective Treatment Period 1 or 2. |
| Measure Participants | 35 | 37 |
| Mean (Standard Deviation) [events (apnea plus hyponea) per hour] |
10.03
(6.799)
|
9.99
(5.878)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.948 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | Mixed effect model | |
| Comments | AHI was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | -0.06 | |
| Confidence Interval |
(2-Sided) 95% -1.95 to 1.83 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | HV Cohort: AHI on Day 1 of Treatment |
|---|---|
| Description | The AHI is the number of apneas and hypopneas per hour of sleep. AHI less than 5 is considered normal. An AHI from 5 to 14 denotes mild sleep apnea, 15 to 30 is moderate, while a greater than 30 AHI is considered severe. |
| Time Frame | Day 1 |
Outcome Measure Data
| Analysis Population Description |
|---|
| PD analysis set included group of participants who received at least 1 dose of study drug in each treatment periods and who had sufficient PD data to derive at least 1 primary PD parameter. |
| Arm/Group Title | HV Cohort: Placebo | HV Cohort: Lemborexant 10 mg | HV Cohort: Lemborexant 25 mg |
|---|---|---|---|
| Arm/Group Description | Eligible healthy adult and elderly participants received lemborexant-matched placebo (3 placebo tablets), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. | Eligible healthy adult and elderly participants received lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets [to maintain blind]), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. | Eligible healthy adult and elderly participants received lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. |
| Measure Participants | 16 | 16 | 16 |
| Mean (Standard Deviation) [events (apnea plus hyponea) per hour] |
4.69
(8.183)
|
5.29
(10.484)
|
3.55
(6.585)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.639 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | Mixed effect model | |
| Comments | AHI was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | 0.52 | |
| Confidence Interval |
(2-Sided) 95% -1.72 to 2.76 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 25 mg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.297 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | mixed effect model | |
| Comments | AHI was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | -1.16 | |
| Confidence Interval |
(2-Sided) 95% -3.40 to 1.08 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | OSA Cohort: AHI on Day 1 of Treatment |
|---|---|
| Description | The AHI is the number of apneas and hypopneas per hour of sleep. AHI less than 5 is considered normal. An AHI from 5 to 14 denotes mild sleep apnea, 15 to 30 is moderate, while a greater than 30 AHI is considered severe. |
| Time Frame | Day 1 |
Outcome Measure Data
| Analysis Population Description |
|---|
| PD analysis set included group of participants who received at least 1 dose of study drug in each treatment periods and who had sufficient PD data to derive at least 1 primary PD parameter. Here, overall number of participants analyzed signifies participants who were evaluable for this outcome measure. |
| Arm/Group Title | OSA Cohort: Placebo | OSA Cohort: Lemborexant 10 mg |
|---|---|---|
| Arm/Group Description | Eligible adult and elderly participants with mild OSA received one lemborexant-matched placebo, tablet, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 in the respective Treatment Period 1 or 2. | Eligible adult and elderly participants with mild OSA received one lemborexant 10 mg, tablet, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 in the respective Treatment Period 1 or 2. |
| Measure Participants | 37 | 36 |
| Mean (Standard Deviation) [events (apnea plus hyponea) per hour] |
10.24
(7.094)
|
10.29
(6.681)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | ||
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.979 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | Mixed effect model | |
| Comments | AHI was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | -0.03 | |
| Confidence Interval |
(2-Sided) 95% -2.22 to 2.17 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | HV Cohort: Percentage of TST During Which SpO2 Was Less Than (<) 90 Percent (%), 85 % and 80 % on Day 1 of Treatment |
|---|---|
| Description | TST was defined as the total time asleep in minutes using PSG. SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 was monitored by noninvasive method known as transmissive pulse oximetry. |
| Time Frame | Day 1 |
Outcome Measure Data
| Analysis Population Description |
|---|
| PD analysis set included group of participants who received at least 1 dose of study drug in each treatment periods and who had sufficient PD data to derive at least 1 primary PD parameter. |
| Arm/Group Title | HV Cohort: Placebo | HV Cohort: Lemborexant 10 mg | HV Cohort: Lemborexant 25 mg |
|---|---|---|---|
| Arm/Group Description | Eligible healthy adult and elderly participants received lemborexant-matched placebo (3 placebo tablets), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. | Eligible healthy adult and elderly participants received lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets [to maintain blind]), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. | Eligible healthy adult and elderly participants received lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. |
| Measure Participants | 16 | 16 | 16 |
| SpO2 <90% |
0.037
(0.0968)
|
0.224
(0.3755)
|
0.287
(0.5555)
|
| SpO2 <85% |
0
(0)
|
0.004
(0.0109)
|
0.047
(0.1516)
|
| SpO2 <80% |
0
(0)
|
0.001
(0.0034)
|
0.003
(0.0077)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | SpO2 is <90% | |
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.095 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | Mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | 0.185 | |
| Confidence Interval |
(2-Sided) 95% -0.034 to 0.405 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 25 mg |
|---|---|---|
| Comments | When SpO2 is <90% | |
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.030 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | Mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | 0.245 | |
| Confidence Interval |
(2-Sided) 95% 0.025 to 0.464 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | SpO2 is <85% | |
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.885 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | Mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | 0.004 | |
| Confidence Interval |
(2-Sided) 95% -0.058 to 0.067 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 25 mg |
|---|---|---|
| Comments | SpO2 is <85% | |
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.158 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | Mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | 0.044 | |
| Confidence Interval |
(2-Sided) 95% -0.018 to 0.107 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Statistical Analysis 5
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | SpO2 is <80% | |
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.462 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | Mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | 0.001 | |
| Confidence Interval |
(2-Sided) 95% -0.002 to 0.005 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Statistical Analysis 6
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 25 mg |
|---|---|---|
| Comments | SpO2 is <80% | |
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.166 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | Mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | 0.002 | |
| Confidence Interval |
(2-Sided) 95% -0.001 to 0.006 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | HV Cohort: Percentage of Participants With at Least One Incident of SpO2 <90% for at Least 30 Seconds During TST on Day 1 of Treatment |
|---|---|
| Description | SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 was monitored by noninvasive method known as transmissive pulse oximetry. TST was defined as the total time asleep in minutes using PSG. |
| Time Frame | Day 1 |
Outcome Measure Data
| Analysis Population Description |
|---|
| PD analysis set included group of participants who received at least 1 dose of study drug in each treatment periods and who had sufficient PD data to derive at least 1 primary PD parameter. |
| Arm/Group Title | HV Cohort: Placebo | HV Cohort: Lemborexant 10 mg | HV Cohort: Lemborexant 25 mg |
|---|---|---|---|
| Arm/Group Description | Eligible healthy adult and elderly participants received lemborexant-matched placebo (3 placebo tablets), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. | Eligible healthy adult and elderly participants received lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets [to maintain blind]), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. | Eligible healthy adult and elderly participants received lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. |
| Measure Participants | 16 | 16 | 16 |
| Number [percentage of participant] |
31.3
|
31.3
|
37.5
|
| Title | OSA Cohort: SpO2 During TST on Day 1 and Day 8 of Treatment |
|---|---|
| Description | SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 was monitored by noninvasive method known as transmissive pulse oximetry. TST was defined as the total time asleep in minutes using PSG. |
| Time Frame | Day 1 and Day 8 |
Outcome Measure Data
| Analysis Population Description |
|---|
| PD analysis set included group of participants who received at least 1 dose of study drug in each treatment periods and who had sufficient PD data to derive at least 1 primary PD parameter. Here, 'number analyzed' signifies participants who were evaluable for analysis at the specified timepoints. |
| Arm/Group Title | OSA Cohort: Placebo | OSA Cohort: Lemborexant 10 mg |
|---|---|---|
| Arm/Group Description | Eligible adult and elderly participants with mild OSA received one lemborexant-matched placebo, tablet, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 in the respective Treatment Period 1 or 2. | Eligible adult and elderly participants with mild OSA received one lemborexant 10 mg, tablet, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 in the respective Treatment Period 1 or 2. |
| Measure Participants | 37 | 37 |
| Day 1 |
94.53
(1.620)
|
94.54
(1.470)
|
| Day 8 |
94.46
(1.316)
|
94.65
(1.539)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | Day 1: Mean SpO2 during TST | |
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.699 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | 0.07 | |
| Confidence Interval |
(2-Sided) 95% -0.31 to 0.46 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | Day 8: Mean SpO2 during TST | |
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.169 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | 0.25 | |
| Confidence Interval |
(2-Sided) 95% -0.11 to 0.61 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | OSA Cohort: Percentage of TST During Which the SpO2 is <90%, 85% and 80 % on Day 1 and Day 8 of Treatment |
|---|---|
| Description | TST was defined as the total time asleep in minutes using PSG. SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 was monitored by noninvasive method known as transmissive pulse oximetry. |
| Time Frame | Day 1 and Day 8 |
Outcome Measure Data
| Analysis Population Description |
|---|
| PD analysis set included group of participants who received at least 1 dose of study drug in each treatment periods and who had sufficient PD data to derive at least 1 primary PD parameter. Here, 'number analyzed' signifies participants who were evaluable for analysis at the specified timepoints. |
| Arm/Group Title | OSA Cohort: Placebo | OSA Cohort: Lemborexant 10 mg |
|---|---|---|
| Arm/Group Description | Eligible adult and elderly participants with mild OSA received one lemborexant-matched placebo, tablet, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 in the respective Treatment Period 1 or 2. | Eligible adult and elderly participants with mild OSA received one lemborexant 10 mg, tablet, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 in the respective Treatment Period 1 or 2. |
| Measure Participants | 37 | 37 |
| Day 1: SpO2 <90% |
1.044
(1.8851)
|
1.362
(2.6170)
|
| Day 1: SpO2 <85% |
0.104
(0.3043)
|
0.170
(0.5132)
|
| Day 1: SpO2 <80% |
0.012
(0.0483)
|
0.014
(0.0433)
|
| Day 8: SpO2 <90% |
1.011
(1.4210)
|
1.102
(1.5469)
|
| Day 8: SpO2 <85% |
0.109
(0.2974)
|
0.162
(0.4350)
|
| Day 8: SpO2 <80% |
0.009
(0.0366)
|
0.015
(0.0603)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | Day 1: SpO2 is <90% | |
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.472 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | 0.312 | |
| Confidence Interval |
(2-Sided) 95% -0.558 to 1.181 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Statistical Analysis 2
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | Day 1: SpO2 is <85% | |
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.479 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | 0.067 | |
| Confidence Interval |
(2-Sided) 95% -0.124 to 0.258 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Statistical Analysis 3
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | Day 1: SpO2 is <80% | |
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.852 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | 0.002 | |
| Confidence Interval |
(2-Sided) 95% -0.019 to 0.023 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Statistical Analysis 4
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | Day 8: SpO2 is <90% | |
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.733 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | 0.088 | |
| Confidence Interval |
(2-Sided) 95% -0.431 to 0.607 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Statistical Analysis 5
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | Day 8: When SpO2 is <85% | |
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.518 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LSM difference |
| Estimated Value | 0.056 | |
| Confidence Interval |
(2-Sided) 95% -0.117 to 0.228 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Statistical Analysis 6
| Statistical Analysis Overview | Comparison Group Selection | HV Cohort: Placebo, HV Cohort: Lemborexant 10 mg |
|---|---|---|
| Comments | Day 8: SpO2 is <80% | |
| Type of Statistical Test | Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.576 |
| Comments | P-Value was at the 0.05 level of significance. | |
| Method | mixed effect model | |
| Comments | SPO2 was analyzed by mixed effect model, which included fixed effects for sequence, period, treatment a random effect for participant within sequence. | |
| Method of Estimation | Estimation Parameter | LS mean difference |
| Estimated Value | 0.006 | |
| Confidence Interval |
(2-Sided) 95% -0.015 to 0.026 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
| Title | OSA Cohort: Percentage of Participants With at Least One Incident of SpO2 <90% for at Least 30 Seconds During TST on Day 1 and Day 8 of Treatment |
|---|---|
| Description | SpO2 is an estimate of the amount of oxygen in the blood. It is the percentage of hemoglobin containing oxygen compared to the total amount of hemoglobin in the blood (that is, oxygenated hemoglobin versus oxygenated and non-oxygenated hemoglobin). SpO2 was monitored by noninvasive method known as transmissive pulse oximetry. TST was defined as the total time asleep in minutes using PSG. |
| Time Frame | Day 1 and Day 8 |
Outcome Measure Data
| Analysis Population Description |
|---|
| PD analysis set included group of participants who received at least 1 dose of study drug in each treatment periods and who had sufficient PD data to derive at least 1 primary PD parameter. |
| Arm/Group Title | OSA Cohort: Placebo | OSA Cohort: Lemborexant 10 mg |
|---|---|---|
| Arm/Group Description | Eligible adult and elderly participants with mild OSA received one lemborexant-matched placebo, tablet, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 in the respective Treatment Period 1 or 2. | Eligible adult and elderly participants with mild OSA received one lemborexant 10 mg, tablet, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 in the respective Treatment Period 1 or 2. |
| Measure Participants | 37 | 37 |
| Day 1: SpO2 <90% |
67.6
|
75.7
|
| Day 8: SpO2 <90% |
75.7
|
83.8
|
Adverse Events
| Time Frame | Baseline up to end of follow up visit (up to 67 days) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Event Reporting Description | Safety analysis set included group of participants who received study drug and had at least 1 postdose safety assessment. | |||||||||
| Arm/Group Title | HV Cohort: Placebo | HV Cohort: Lemborexant 10 mg | HV Cohort: Lemborexant 25 mg | OSA Cohort: Placebo | OSA Cohort: Lemborexant 10 mg | |||||
| Arm/Group Description | Eligible healthy adult and elderly participants received lemborexant-matched placebo (3 placebo tablets), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. | Eligible healthy adult and elderly participants received lemborexant 10 mg (1 lemborexant 10 mg tablet and 2 matching placebo tablets [to maintain blind]), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. | Eligible healthy adult and elderly participants received lemborexant 25 mg (2 lemborexant 10 mg tablets and 1 lemborexant 5 mg tablet), orally, once, in the evening (within 5 minutes of lights off) of Day 1 in the respective Treatment Period 1, 2 or 3. | Eligible adult and elderly participants with mild OSA received one lemborexant-matched placebo, tablet, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 in the respective Treatment Period 1 or 2. | Eligible adult and elderly participants with mild OSA received one lemborexant 10 mg, tablet, orally, once, in the evening (within 5 minutes of lights off) of Day 1 through Day 8 in the respective Treatment Period 1 or 2. | |||||
All Cause Mortality |
||||||||||
| HV Cohort: Placebo | HV Cohort: Lemborexant 10 mg | HV Cohort: Lemborexant 25 mg | OSA Cohort: Placebo | OSA Cohort: Lemborexant 10 mg | ||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/16 (0%) | 0/16 (0%) | 0/17 (0%) | 0/38 (0%) | 0/38 (0%) | |||||
Serious Adverse Events |
||||||||||
| HV Cohort: Placebo | HV Cohort: Lemborexant 10 mg | HV Cohort: Lemborexant 25 mg | OSA Cohort: Placebo | OSA Cohort: Lemborexant 10 mg | ||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/16 (0%) | 0/16 (0%) | 0/17 (0%) | 0/38 (0%) | 0/38 (0%) | |||||
Other (Not Including Serious) Adverse Events |
||||||||||
| HV Cohort: Placebo | HV Cohort: Lemborexant 10 mg | HV Cohort: Lemborexant 25 mg | OSA Cohort: Placebo | OSA Cohort: Lemborexant 10 mg | ||||||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 1/16 (6.3%) | 1/16 (6.3%) | 4/17 (23.5%) | 5/38 (13.2%) | 6/38 (15.8%) | |||||
| Eye disorders | ||||||||||
| Photopsia | 0/16 (0%) | 0/16 (0%) | 1/17 (5.9%) | 0/38 (0%) | 0/38 (0%) | |||||
| Gastrointestinal disorders | ||||||||||
| Abdominal pain upper | 0/16 (0%) | 0/16 (0%) | 0/17 (0%) | 1/38 (2.6%) | 0/38 (0%) | |||||
| Haemorrhoids | 0/16 (0%) | 0/16 (0%) | 0/17 (0%) | 0/38 (0%) | 1/38 (2.6%) | |||||
| General disorders | ||||||||||
| Asthenia | 0/16 (0%) | 0/16 (0%) | 0/17 (0%) | 0/38 (0%) | 1/38 (2.6%) | |||||
| Immune system disorders | ||||||||||
| Seasonal allergy | 0/16 (0%) | 0/16 (0%) | 1/17 (5.9%) | 0/38 (0%) | 0/38 (0%) | |||||
| Infections and infestations | ||||||||||
| Nasopharyngitis | 0/16 (0%) | 0/16 (0%) | 0/17 (0%) | 1/38 (2.6%) | 0/38 (0%) | |||||
| Vaginal infection | 0/16 (0%) | 0/16 (0%) | 0/17 (0%) | 0/38 (0%) | 1/38 (2.6%) | |||||
| Musculoskeletal and connective tissue disorders | ||||||||||
| Arthralgia | 0/16 (0%) | 0/16 (0%) | 1/17 (5.9%) | 0/38 (0%) | 0/38 (0%) | |||||
| Muscular weakness | 0/16 (0%) | 0/16 (0%) | 1/17 (5.9%) | 0/38 (0%) | 0/38 (0%) | |||||
| Myalgia | 0/16 (0%) | 0/16 (0%) | 0/17 (0%) | 0/38 (0%) | 1/38 (2.6%) | |||||
| Nervous system disorders | ||||||||||
| Dizziness | 0/16 (0%) | 0/16 (0%) | 1/17 (5.9%) | 1/38 (2.6%) | 0/38 (0%) | |||||
| Somnolence | 0/16 (0%) | 1/16 (6.3%) | 1/17 (5.9%) | 0/38 (0%) | 2/38 (5.3%) | |||||
| Headache | 0/16 (0%) | 0/16 (0%) | 0/17 (0%) | 1/38 (2.6%) | 0/38 (0%) | |||||
| Reproductive system and breast disorders | ||||||||||
| Endometriosis | 0/16 (0%) | 0/16 (0%) | 0/17 (0%) | 0/38 (0%) | 1/38 (2.6%) | |||||
| Respiratory, thoracic and mediastinal disorders | ||||||||||
| Rhinitis allergic | 1/16 (6.3%) | 0/16 (0%) | 0/17 (0%) | 0/38 (0%) | 0/38 (0%) | |||||
| Vascular disorders | ||||||||||
| Hypertension | 0/16 (0%) | 0/16 (0%) | 0/17 (0%) | 1/38 (2.6%) | 0/38 (0%) | |||||
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
Results Point of Contact
| Name/Title | Eisai Medical Information |
|---|---|
| Organization | Eisai Inc. |
| Phone | +1-888-274-2378 |
| esi_medinfo@eisai.com |
- E2006-A001-102